Co-Diagnostics, Inc. (CODX)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-05-14

Key Insights

Co-Diagnostics announced Q1 2026 financial results on May 14, 2026, with the detailed press release furnished as Exhibit 99.1 but not formally filed, limiting the extent of liability associated with the disclosure.
The filing indicates the company is a small business issuer trading on Nasdaq Capital Market under ticker CODX, suggesting a smaller-cap diagnostics company that may face liquidity or analyst coverage constraints.
The 8-K was signed by CFO Brian Brown as the principal financial officer, indicating standard earnings announcement procedures with no indication of material agreements, leadership changes, or extraordinary events that would typically drive stock movement.

Quarterly Report Filed: 2026-05-14

Key Insights

The filing content provided is incomplete and consists primarily of XML metadata tags without substantive financial data, making it impossible to extract meaningful revenue trends, profitability metrics, or operational performance indicators.
Customer concentration risk is identified as a disclosure item with references to multiple customer segments, suggesting potential dependency on key customers that warrants investor attention regarding revenue stability.
The document references various equity instruments including preferred stock, common stock, warrants, and RSUs with multiple measurement inputs, indicating an active capital structure that may impact shareholder dilution.
The presence of R&D and in-process research and development line items suggests Co-Diagnostics maintains an ongoing investment in product development, though specific allocation amounts and expected outcomes are not visible in the provided excerpt.

Current Report Filed: 2026-03-31

Key Insights

Co-Diagnostics reported financial results for the year ended December 31, 2025, providing investors with updated information on the company's performance.
The company did not disclose any details on revenue, margins, or guidance, limiting the ability to assess the financial health and future prospects.
Without substantive information on the company's operations and outlook, investors have limited visibility into the current state and trajectory of the business.

Annual Report Filed: 2026-03-31

Key Insights

The company experienced significant growth in product and grant revenue from 2024 to 2025, indicating strong demand for their offerings.
Customer and grant agency concentration risks are present, with a few key customers and agencies accounting for a large portion of revenue and accounts receivable.
The company made a strategic acquisition of Co-Mira Diagnostics in October 2025, which could expand their product portfolio and market reach.

Current Report Filed: 2026-01-13

Key Insights

Co-Diagnostics, Inc. has been notified by Nasdaq that its common stock will be delisted from the Nasdaq Capital Market due to its failure to meet the minimum bid price requirement of $1.00 per share.
The company plans to request a hearing before the Nasdaq Hearings Panel to address the bid price deficiency, but its shares will be suspended from trading on Nasdaq effective January 14, 2026.
The company's shares will likely trade on the Pink Limited Information tier of the OTC Market under the current trading symbol 'CODX' after the suspension.

Current Report Filed: 2025-12-30

Key Insights

Co-Diagnostics, Inc. announced a 1-for-30 reverse stock split effective January 1, 2026, which should help the stock meet Nasdaq's minimum share price requirement and maintain its exchange listing.
The reverse split will reduce the number of outstanding shares from approximately 62.8 million to around 2.1 million, potentially improving trading liquidity and visibility for investors.
The company's press release indicates there will be no changes to the rights or preferences of the common stock as a result of the reverse split.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.